Placida PLUS Side effects

Rating: 5 - 1 review(s)
sponsored
What is the dose of your medication?

Consists of escitalopram, etizolam

What are the possible side effects of Escitalopram (Placida PLUS)?

Get emergency medical help if you have signs of an allergic reaction to Escitalopram (Placida PLUS): skin rash or hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.

Call your doctor at once if you have:

  • blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;

  • racing thoughts, unusual risk-taking behavior, feelings of extreme happiness or sadness;

  • low levels of sodium in the body - headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady; or

  • severe nervous system reaction - very stiff (rigid) muscles, high fever, sweating, confusion, fast or uneven heartbeats, tremors, feeling like you might pass out.

Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.

Common Escitalopram (Placida PLUS) side effects may include:

  • dizziness, drowsiness, weakness;

  • sweating, feeling shaky or anxious;

  • sleep problems (insomnia);

  • dry mouth, loss of appetite;

  • nausea, constipation;

  • yawning;

  • weight changes; or

  • decreased sex drive, impotence, or difficulty having an orgasm.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects of Escitalopram (Placida PLUS) in details

A side effect of any drug can be defined as the unwanted or undesired effect produced by the drug. The side effect can be major or in few medications minor that can be ignored. Side effects not only vary from drug to drug, but it also depends on the dose of the drug, the individual sensitivity of the person, brand or company which manufactures it. If side effects overweigh the actual effect of the medicine, it may be difficult to convince the patient to take the drug. Few patients get specific side effects to specific drugs; in that case, a doctor replaces the drug with another. If you feel any side effect and it troubles you, do not forget to share with your healthcare practitioner.
sponsored

Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Clinical Trial Data Sources

Pediatrics (6 -17 years)

Adverse events were collected in 576 pediatric patients (286 Escitalopram (Placida PLUS), 290 placebo) with major depressive disorder in double-blind placebo-controlled studies. Safety and effectiveness of Escitalopram (Placida PLUS) in pediatric patients less than 12 years of age has not been established.

Adults

Adverse events information for Escitalopram (Placida PLUS) was collected from 715 patients with major depressive disorder who were exposed to Escitalopram (Placida PLUS) and from 592 patients who were exposed to placebo in double-blind, placebo-controlled trials. An additional 284 patients with major depressive disorder were newly exposed to Escitalopram (Placida PLUS) in open-label trials. The adverse event information for Escitalopram (Placida PLUS) in patients with GAD was collected from 429 patients exposed to Escitalopram (Placida PLUS) and from 427 patients exposed to placebo in double-blind, placebo-controlled trials.

Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events.

The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

Adverse Events Associated with Discontinuation of Treatment

Major Depressive Disorder

Pediatrics (6 -17 years)

Adverse events were associated with discontinuation of 3.5% of 286 patients receiving Escitalopram (Placida PLUS) and 1% of 290 patients receiving placebo. The most common adverse event (incidence at least 1% for Escitalopram (Placida PLUS) and greater than placebo) associated with discontinuation was insomnia (1% Escitalopram (Placida PLUS), 0% placebo).

Adults

Among the 715 depressed patients who received Escitalopram (Placida PLUS) in placebo-controlled trials, 6% discontinued treatment due to an adverse event, as compared to 2% of 592 patients receiving placebo. In two fixed-dose studies, the rate of discontinuation for adverse events in patients receiving 10 mg/day Escitalopram (Placida PLUS) was not significantly different from the rate of discontinuation for adverse events in patients receiving placebo. The rate of discontinuation for adverse events in patients assigned to a fixed dose of 20 mg/day Escitalopram (Placida PLUS) was 10%, which was significantly different from the rate of discontinuation for adverse events in patients receiving 10 mg/day Escitalopram (Placida PLUS) (4%) and placebo (3%). Adverse events that were associated with the discontinuation of at least 1% of patients treated with Escitalopram (Placida PLUS), and for which the rate was at least twice that of placebo, were nausea (2%) and ejaculation disorder (2% of male patients).

Generalized Anxiety Disorder

Adults

Among the 429 GAD patients who received Escitalopram (Placida PLUS) 10-20 mg/day in placebo-controlled trials, 8% discontinued treatment due to an adverse event, as compared to 4% of 427 patients receiving placebo. Adverse events that were associated with the discontinuation of at least 1% of patients treated with Escitalopram (Placida PLUS), and for which the rate was at least twice the placebo rate, were nausea (2%), insomnia (1%), and fatigue (1%).

Incidence of Adverse Reactions in Placebo-Controlled Clinical Trials

Major Depressive Disorder

Pediatrics (6 -17 years)

The overall profile of adverse reactions in pediatric patients was generally similar to that seen in adult studies, as shown in Table 2. However, the following adverse reactions (excluding those which appear in Table 2 and those for which the coded terms were uninformative or misleading) were reported at an incidence of at least 2% for Escitalopram (Placida PLUS) and greater than placebo: back pain, urinary tract infection, vomiting, and nasal congestion.

Adults

The most commonly observed adverse reactions in Escitalopram (Placida PLUS) patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were insomnia, ejaculation disorder (primarily ejaculatory delay), nausea, sweating increased, fatigue, and somnolence.

Table 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred among 715 depressed patients who received Escitalopram (Placida PLUS) at doses ranging from 10 to 20 mg/day in placebo-controlled trials. Events included are those occurring in 2% or more of patients treated with Escitalopram (Placida PLUS) and for which the incidence in patients treated with Escitalopram (Placida PLUS) was greater than the incidence in placebo-treated patients.

TABLE 2 : Treatment-Emergent Adverse Reactions observed with a frequency of ≥ 2% and greater than placebo for Major Depressive Disorder

Adverse Reaction Escitalopram (Placida PLUS)

(N=715) %

Placebo

(N=592) %

Autonomic Nervous System Disorders
Dry Mouth 6% 5%
Sweating Increased 5% 2%
Central & Peripheral Nervous System Disorders
Dizziness 5% 3%
Gastrointestinal Disorders
Nausea 15% 7%
Diarrhea 8% 5%
Constipation 3% 1%
Indigestion 3% 1%
Abdominal Pain 2% 1%
General
Influenza-like Symptoms 5% 4%
Fatigue 5% 2%
Psychiatric Disorders
Insomnia 9% 4%
Somnolence 6% 2%
Appetite Decreased 3% 1%
Libido Decreased 3% 1%
Respiratory System Disorders
Rhinitis 5% 4%
Sinusitis 3% 2%
Urogenital
Ejaculation DisorderDenominator used was for females only (N=247 Escitalopram (Placida PLUS); N=232 placebo).

Dose Dependency of Adverse Reactions

The potential dose dependency of common adverse reactions (defined as an incidence rate of ≥ 5% in either the 10 mg or 20 mg Escitalopram (Placida PLUS) groups) was examined on the basis of the combined incidence of adverse reactions in two fixed-dose trials. The overall incidence rates of adverse events in 10 mg Escitalopram (Placida PLUS)-treated patients (66%) was similar to that of the placebo-treated patients (61%), while the incidence rate in 20 mg/day Escitalopram (Placida PLUS)-treated patients was greater (86%). Table 4 shows common adverse reactions that occurred in the 20 mg/day Escitalopram (Placida PLUS) group with an incidence that was approximately twice that of the 10 mg/day Escitalopram (Placida PLUS) group and approximately twice that of the placebo group.

TABLE 4 : Incidence of Common Adverse Reactions in Patients with Major Depressive Disorder

Adverse Reaction Placebo

(N=311)

10 mg/day Escitalopram (Placida PLUS)

(N=310)

20 mg/day Escitalopram (Placida PLUS)

(N=125)

Insomnia 4% 7% 14%
Diarrhea 5% 6% 14%
Dry Mouth 3% 4% 9%
Somnolence 1% 4% 9%
Dizziness 2% 4% 7%
Sweating Increased < 1% 3% 8%
Constipation 1% 3% 6%
Fatigue 2% 2% 6%
Indigestion 1% 2% 6%

Male and Female Sexual Dysfunction with SSRIs

Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences.

Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to underestimate their actual incidence.

TABLE 5 : Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials

Adverse Event Escitalopram (Placida PLUS) Placebo
In Males Only
(N=407) (N = 383)
Ejaculation Disorder (primarily ejaculatory delay) 12% 1%
Libido Decreased 6% 2%
Impotence 2% < 1%
In Females Only
(N=737) (N=636)
Libido Decreased 3% 1%
Anorgasmia 3% < 1%

There are no adequately designed studies examining sexual dysfunction with Escitalopram (Placida PLUS) treatment.

Priapism has been reported with all SSRIs.

While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.

Vital Sign Changes

Escitalopram (Placida PLUS) and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with Escitalopram (Placida PLUS) treatment. In addition, a comparison of supine and standing vital sign measures in subjects receiving Escitalopram (Placida PLUS) indicated that Escitalopram (Placida PLUS) treatment is not associated with orthostatic changes.

Weight Changes

Patients treated with Escitalopram (Placida PLUS) in controlled trials did not differ from placebo-treated patients with regard to clinically important change in body weight.

Laboratory Changes

Escitalopram (Placida PLUS) and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables, and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with Escitalopram (Placida PLUS) treatment.

ECG Changes

Electrocardiograms from Escitalopram (Placida PLUS) (N=625) and placebo (N=527) groups were compared with respect to outliers defined as subjects with QTc changes over 60 msec from baseline or absolute values over 500 msec post-dose, and subjects with heart rate increases to over 100 bpm or decreases to less than 50 bpm with a 25% change from baseline (tachycardic or bradycardic outliers, respectively). None of the patients in the Escitalopram (Placida PLUS) group had a QTcF interval > 500 msec or a prolongation > 60 msec compared to 0.2% of patients in the placebo group. The incidence of tachycardic outliers was 0.2% in the Escitalopram (Placida PLUS) and the placebo group. The incidence of bradycardic outliers was 0.5% in the Escitalopram (Placida PLUS) group and 0.2% in the placebo group.

QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 113 healthy subjects. The maximum mean (95% upper confidence bound) difference from placebo arm were 4.5 (6.4) and 10.7 (12.7) msec for 10 mg and supratherapeutic 30 mg Escitalopram (Placida PLUS) given once daily, respectively. Based on the established exposure-response relationship, the predicted QTcF change from placebo arm (95% confidence interval) under the Cmax for the dose of 20 mg is 6.6 (7.9) msec. Escitalopram (Placida PLUS) 30 mg given once daily resulted in mean Cmax of 1.7-fold higher than the mean Cmax for the maximum recommended therapeutic dose at steady state (20 mg). The exposure under supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg.

Other Reactions Observed During the Premarketing Evaluation of Escitalopram (Placida PLUS)

Following is a list of treatment-emergent adverse events, as defined in the introduction to the ADVERSE REACTIONS section, reported by the 1428 patients treated with Escitalopram (Placida PLUS) for periods of up to one year in double-blind or open-label clinical trials during its premarketing evaluation. The listing does not include those events already listed in Tables 2 & 3, those events for which a drug cause was remote and at a rate less than 1% or lower than placebo, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life threatening. Events are categorized by body system. Events of major clinical importance are described in the WARNINGS AND PRECAUTIONS section.

Cardiovascular - hypertension, palpitation.

Central and Peripheral Nervous System Disorders - light-headed feeling, migraine.

Gastrointestinal Disorders - abdominal cramp, heartburn, gastroenteritis.

General - allergy, chest pain, fever, hot flushes, pain in limb.

Metabolic and Nutritional Disorders - increased weight.

Musculoskeletal System Disorders - arthralgia, myalgia jaw stiffness.

Psychiatric Disorders - appetite increased, concentration impaired, irritability.

Reproductive Disorders/Female - menstrual cramps, menstrual disorder.

Respiratory System Disorders - bronchitis, coughing, nasal congestion, sinus congestion, sinus headache.

Skin and Appendages Disorders - rash.

Special Senses - vision blurred, tinnitus.

Urinary System Disorders - urinary frequency, urinary tract infection.

Post-Marketing Experience

Adverse Reactions Reported Subsequent to the Marketing of Escitalopram (Placida PLUS)

The following additional adverse reactions have been identified from spontaneous reports of Escitalopram (Placida PLUS) received worldwide. These adverse reactions have been chosen for inclusion because of a combination of seriousness, frequency of reporting, or potential causal connection to Escitalopram (Placida PLUS) and have not been listed elsewhere in labeling. However, because these adverse reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events include:

Blood and Lymphatic System Disorders: anemia, agranulocytis, aplastic anemia, hemolytic anemia, idiopathic thrombocytopenia purpura, leukopenia, thrombocytopenia.

Cardiac Disorders: atrial fibrillation, bradycardia, cardiac failure, myocardial infarction, tachycardia, torsade de pointes, ventricular arrhythmia, ventricular tachycardia.

Ear and labyrinth disorders: vertigo

Endocrine Disorders: diabetes mellitus, hyperprolactinemia, SIADH.

Eye Disorders: angle closure glaucoma, diplopia, mydriasis, visual disturbance.

Gastrointestinal Disorder: dysphagia, gastrointestinal hemorrhage, gastroesophageal reflux, pancreatitis, rectal hemorrhage.

General Disorders and Administration Site Conditions: abnormal gait, asthenia, edema, fall, feeling abnormal, malaise.

Hepatobiliary Disorders: fulminant hepatitis, hepatic failure, hepatic necrosis, hepatitis.

Immune System Disorders: allergic reaction, anaphylaxis.

Investigations: bilirubin increased, decreased weight, electrocardiogram QT prolongation, hepatic enzymes increased, hypercholesterolemia, INR increased, prothrombin decreased.

Metabolism and Nutrition Disorders: hyperglycemia, hypoglycemia, hypokalemia, hyponatremia.

Musculoskeletal and Connective Tissue Disorders: muscle cramp, muscle stiffness, muscle weakness, rhabdomyolysis.

Nervous System Disorders: akathisia, amnesia, ataxia, choreoathetosis, cerebrovascular accident, dysarthria, dyskinesia, dystonia, extrapyramidal disorders, grand mal seizures (or convulsions), hypoaesthesia, myoclonus, nystagmus, Parkinsonism, restless legs, seizures, syncope, tardive dyskinesia, tremor.

Pregnancy, Puerperium and Perinatal Conditions: spontaneous abortion.

Psychiatric Disorders: acute psychosis, aggression, agitation, anger, anxiety, apathy, completed suicide, confusion, depersonalization, depression aggravated, delirium, delusion, disorientation, feeling unreal, hallucinations (visual and auditory), mood swings, nervousness, nightmare, panic reaction, paranoia, restlessness, self-harm or thoughts of self-harm, suicide attempt, suicidal ideation, suicidal tendency.

Renal and Urinary Disorders: acute renal failure, dysuria, urinary retention.

Reproductive System and Breast Disorders: menorrhagia, priapism.

Respiratory, Thoracic and Mediastinal Disorders: dyspnea, epistaxis, pulmonary embolism, pulmonary hypertension of the newborn.

Skin and Subcutaneous Tissue Disorders: alopecia, angioedema, dermatitis, ecchymosis, erythema multiforme, photosensitivity reaction, Stevens Johnson Syndrome, toxic epidermal necrolysis, urticaria.

Vascular Disorders: deep vein thrombosis, flushing, hypertensive crisis, hypotension, orthostatic hypotension, phlebitis, thrombosis.

What is the most important information I should know about Escitalopram (Placida PLUS)?

  • Escitalopram (Placida PLUS) may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Escitalopram (Placida PLUS) with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
  • Do not drink alcohol while you are using Escitalopram (Placida PLUS).
  • Check with your doctor before you use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Escitalopram (Placida PLUS); it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.
  • One to 4 weeks may pass before your symptoms improve. Do NOT take more than the recommended dose, change your dose, or use Escitalopram (Placida PLUS) for longer than prescribed without checking with your doctor.
  • Children, teenagers, and young adults who take Escitalopram (Placida PLUS) may be at increased risk for suicidal thoughts or actions. Watch all patients who take Escitalopram (Placida PLUS) closely. Contact the doctor at once if new, worsened, or sudden symptoms such as depressed mood; anxious, restless, or irritable behavior; panic attacks; or any unusual change in mood or behavior occur. Contact the doctor right away if any signs of suicidal thoughts or actions occur.
  • Escitalopram (Placida PLUS) and a medicine called citalopram have the same active ingredient. Do not take Escitalopram (Placida PLUS) if you are also taking citalopram.
  • If your doctor tells you to stop taking Escitalopram (Placida PLUS), you will need to wait for several weeks before beginning to take certain other medicines (eg, MAOIs, nefazodone). Ask your doctor when you should start to take your new medicines after you have stopped taking Escitalopram (Placida PLUS).
  • Escitalopram (Placida PLUS) may rarely cause a prolonged, painful erection. This could happen even when you are not having sex. If this is not treated right away, it could lead to permanent sexual problems such as impotence. Contact your doctor right away if this happens.
  • Serotonin syndrome is a possibly fatal syndrome that can be caused by Escitalopram (Placida PLUS). Your risk may be greater if you take Escitalopram (Placida PLUS) with certain other medicines (eg, "triptans," MAOIs). Symptoms may include agitation; confusion; hallucinations; coma; fever; fast or irregular heartbeat; tremor; excessive sweating; and nausea, vomiting, or diarrhea. Contact your doctor at once if you have any of these symptoms.
  • Certain antidepressants, including Escitalopram (Placida PLUS), may increase the risk of bleeding. Sometimes, bleeding can be life-threatening. Discuss any questions or concerns with your doctor.
  • Some people may be at risk for eye problems from Escitalopram (Placida PLUS). Your doctor may want you to have an eye exam to see if you are at risk for these eye problems. Call your doctor right away if you have eye pain, vision changes, or swelling or redness in or around the eye.
  • Use Escitalopram (Placida PLUS) with caution in the ELDERLY; they may be more sensitive to its effects, especially low blood sodium levels.
  • Caution is advised when using Escitalopram (Placida PLUS) in CHILDREN; they may be more sensitive to its effects, especially increased risk of suicidal thoughts or actions.
  • Escitalopram (Placida PLUS) should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.
  • Escitalopram (Placida PLUS) may cause weight changes. CHILDREN and teenagers may need regular weight and growth checks while they take Escitalopram (Placida PLUS).
  • PREGNANCY and BREAST-FEEDING: Escitalopram (Placida PLUS) may cause harm to the fetus if it is used during the last 3 months of pregnancy. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Escitalopram (Placida PLUS) while you are pregnant. Escitalopram (Placida PLUS) is found in breast milk. Do not breast-feed while taking Escitalopram (Placida PLUS).

Escitalopram (Placida PLUS) contraindications

Contraindication can be described as a special circumstance or a disease or a condition wherein you are not supposed to use the drug or undergo particular treatment as it can harm the patient; at times, it can be dangerous and life threatening as well. When a procedure should not be combined with other procedure or when a medicine cannot be taken with another medicine, it is called Relative contraindication. Contraindications should be taken seriously as they are based on the relative clinical experience of health care providers or from proven research findings.
sponsored

Do not take Escitalopram (Placida PLUS) together with a monoamine oxidase inhibitor (MAOI) such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate). You must wait at least 14 days after stopping an MAOI before you can take Escitalopram (Placida PLUS). After you stop taking Escitalopram (Placida PLUS), you must wait at least 14 days before you start taking an MAOI.

You may have thoughts about suicide when you first start taking an antidepressant, especially if you are younger than 24 years old. Your doctor will need to check you at regular visits for at least the first 12 weeks of treatment.

Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.

Tell your doctor right away if you become pregnant while taking this medication. Escitalopram (Placida PLUS) may cause heart defects or serious lung problems in a newborn if you take the medication during pregnancy. However, you may have a relapse of depression if you stop taking your antidepressant. Do not start or stop taking Escitalopram (Placida PLUS) during pregnancy without your doctor's advice.

It is dangerous to try and purchase Escitalopram (Placida PLUS) on the Internet or from vendors outside of the United States. Medications distributed from Internet sales may contain dangerous ingredients, or may not be distributed by a licensed pharmacy. Samples of Escitalopram (Placida PLUS) purchased on the Internet have been found to contain haloperidol (Haldol), a potent antipsychotic drug with dangerous side effects. For more information, contact the U.S. Food and Drug Administration (FDA) or visit www.fda.gov/buyonlineguide.

Side effects of Etizolam (Placida PLUS) in details

A side effect of any drug can be defined as the unwanted or undesired effect produced by the drug. The side effect can be major or in few medications minor that can be ignored. Side effects not only vary from drug to drug, but it also depends on the dose of the drug, the individual sensitivity of the person, brand or company which manufactures it. If side effects overweigh the actual effect of the medicine, it may be difficult to convince the patient to take the drug. Few patients get specific side effects to specific drugs; in that case, a doctor replaces the drug with another. If you feel any side effect and it troubles you, do not forget to share with your healthcare practitioner.
sponsored

Drowsiness, sedation, muscle weakness and ataxia. Less frequently, vertigo, headache, confusion, depression, slurred speech or dysarthria, changes in libido, tremor, visual disturbances, urinary retention or incontinence, GI disturbances, changes in salivation and amnesia.

Etizolam (Placida PLUS) contraindications

Contraindication can be described as a special circumstance or a disease or a condition wherein you are not supposed to use the drug or undergo particular treatment as it can harm the patient; at times, it can be dangerous and life threatening as well. When a procedure should not be combined with other procedure or when a medicine cannot be taken with another medicine, it is called Relative contraindication. Contraindications should be taken seriously as they are based on the relative clinical experience of health care providers or from proven research findings.

Acute narrow-angle glaucoma; myasthenia gravis; resp depression; coma; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment. Chronic psychosis. Phobic or obsessional states; may precipitate suicide or aggressive behavior, not to be used alone to treat depression or anxiety associated with depression. Porphyria. Pregnancy and lactation. Neonates.

References

  1. European Chemicals Agency - ECHA. "(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
  2. European Chemicals Agency - ECHA. "4-(2-Chloro-phenyl)-2-ethyl-9-methyl-6H-1-thia-5,7,8,9a-tetraazacyclopenta[e]azulene: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
  3. NCIt. "Escitalopram: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Placida PLUS are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Placida PLUS. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

1 consumer reported side effects

Did you experience side effects while taking Placida PLUS drug?
According to the report by ndrugs.com, the below mentioned statistics discuss the number of people who experienced side effects after taking Placida PLUS drug. Every drug produces at least minor unwanted effects, which we call side effects. The side effects can be bothersome, or they can be minor so patients do not know they are experiencing them. The side effects of the drug depend on the individual, severity of disease, symptom, and associated conditions in the patient. The most deciding factor is the drug dosage. The higher the dosage, the higher the therapeutic result, and the more side effects. Every patient need not have the same intensity of side effect. When the side effects are greater, immediately consult your health care provider.
Users%
No side effects1
100.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 26 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 ndrugs.com All Rights Reserved